105 related articles for article (PubMed ID: 10327295)
1. Effect of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G
Dan Med Bull; 1999 Apr; 46(2):118-26. PubMed ID: 10327295
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
3. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G; Skousgaard SG; Daugaard H; Schifter S; Kollerup G; Sørensen OH
Calcif Tissue Int; 1993 Oct; 53(4):232-6. PubMed ID: 8275350
[TBL] [Abstract][Full Text] [Related]
5. Nasal calcitonin for treatment of established osteoporosis.
Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
[TBL] [Abstract][Full Text] [Related]
6. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
7. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
8. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
[TBL] [Abstract][Full Text] [Related]
9. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
Hinchcliffe M; Jabbal-Gill I; Smith A
J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
11. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.
Schipper NG; Romeijn SG; Verhoef J; Merkus FW
Calcif Tissue Int; 1994 Jan; 54(1):50-5. PubMed ID: 8118754
[TBL] [Abstract][Full Text] [Related]
12. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
van der Wiel HE; Lips P; Nauta J; Kwakkel G; Hazenberg G; Netelenbos JC; van der Vijgh WJ
J Bone Miner Res; 1993 Dec; 8(12):1459-65. PubMed ID: 8304047
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin load test to assess the efficacy of salmon calcitonin.
Stepan JJ; Zikán V
Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
15. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
16. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
Grigoriou O; Papoulias I; Vitoratos N; Papadias C; Konidaris S; Antoniou G; Chryssikopoulos A
Maturitas; 1997 Dec; 28(2):147-51. PubMed ID: 9522322
[TBL] [Abstract][Full Text] [Related]
17. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women.
Overgaard K; Agnusdei D; Hansen MA; Maioli E; Christiansen C; Gennari C
J Clin Endocrinol Metab; 1991 Feb; 72(2):344-9. PubMed ID: 1846873
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Dec; 8():12. PubMed ID: 19055791
[TBL] [Abstract][Full Text] [Related]
19. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcitonin on bone and connective tissue metabolism in hemiplegic patients: a two-year prospective study.
Uebelhart D; Hartmann DJ; Barbezat S; Mermillod B; Chantraine A
Clin Rehabil; 1999 Oct; 13(5):384-91. PubMed ID: 10498345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
